To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Melanoma patient-derived … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

Journal article
Authors Berglind Osk Einarsdottir
Roger Olofsson Bagge
Joydeep Bhadury
Henrik Jespersen
Jan Mattsson
Lisa M Nilsson
Katarina Truvé
Marcela Dávila López
Peter Naredi
Ola Nilsson
Ulrika Stierner
Lars Ny
Jonas A Nilsson
Published in Oncotarget
Volume 5
Issue 20
Pages 9609-18
ISSN 1949-2553
Publication year 2014
Published at Institute of Clinical Sciences, Department of Surgery
Institute of Clinical Sciences, Department of Oncology
Institute of Biomedicine
Pages 9609-18
Language en
Links www.ncbi.nlm.nih.gov/entrez/query.f...
Subject categories Cancer and Oncology, Surgery

Abstract

The development of novel therapies against melanoma would benefit from individualized tumor models to ensure the rapid and accurate identification of biomarkers of therapy response. Previous studies have suggested that patient-derived xenografts (PDXes) could be useful. However, the utility of PDXes in guiding real-time treatment decisions has only been reported in anecdotal forms. Here tumor biopsies from patients with stage III and IV metastatic malignant melanoma were transplanted into immunocompromised mice to generate PDXes. 23/26 melanoma biopsies generated serially transplantable PDX models, and their histology, mutation status and expression profile resembled their corresponding patient biopsy. The potential treatment for one patient was revealed by an in vitro drug screen and treating PDXes with the MEK inhibitor trametinib. In another patient, the BRAF mutation predicted the response of both the patient and its corresponding PDXes to MAPK-targeted therapy. Importantly, in this unselected group of patients, the time from biopsy for generation of PDXes until death was significantly longer than the time required to reach the treatment phase of the PDXes. Thus, it could be clinically meaningful to use this type of platform for melanoma patients as a pre-selection tool in clinical trials.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?